Medications to Expedite Rehabilitation of the Traumatic Brain Injury Patient

Size: px
Start display at page:

Download "Medications to Expedite Rehabilitation of the Traumatic Brain Injury Patient"

Transcription

1 Medications to Expedite Rehabilitation of the Traumatic Brain Injury Patient Austin Trauma & Critical Care Conference May 31, 2018 Kristin Wong, MD, FAAPMR Assistant Professor, Physical Medicine & Rehabilitation

2 Primary vs. Secondary Brain Injury

3 Neurotransmitter Storm Beauchamp et al. (2008)

4 Neuromodulation with Pharmocotherapy Limited level 1 evidence for most medications Majority of studies are limited to small RCT s or case series No medication has received approval from U.S. FDA for the treatment of any posttraumatic neuropsychiatric problem, so all such treatments must be considered off label

5 Medications reported to improve cognition after TBI Cholinergic Agents Physostigmine (not recommended due to systemic effects) Cytidine-5 -diphosphocholine Cholinesterase inhibitors Donepezil, rivastigmine, galantamine Catecholaminergic agents Psychostimulants (methylphenidate, dextroamphetamine) Amantadine Bromocriptine Levodopa Selegiline Other Agents TCA s?other antidepressants (SSRIs, SNRIs)?Atomoxetine (selective norepinephrine reuptake inhibitor)? Pergolide, pramipexole, ropinirole (dopamine receptor agonists)?guanfacine (selective alpha 2a-adrenergic agonist)?lamotrigine?memantine (N-methyle-D-aspartate receptor antagonist)? = potentially useful agents that have very limited or no support within the clinical TBI literature

6 Amantadine

7 Amantadine Dopamine agonist with weak NMDA antagonistic properties Has been shown to accelerate functional recovery and arousal in patients with post-traumatic disorders of consciousness. (Giacino et al, 2012) No reliable data to support the efficacy of pharmacologic intervention in the comatose (Ranchos I) patient Dosing: mg BID at breakfast and lunch, capsule or syrup. Renally dose. Timing: Start 3 days 5 months post-injury

8 Methylphenidate Psychostimulant, used for ADHD Dopamine > norepinephrine reuptake inhibitor Dosing: 5-15mg po BID at breakfast and lunch Randomized, double blind crossover design showed that methylphenidate enhances processing speed and increases attention and concentration (Willmott and Ponsford 2009) Greatest medication response was observed in those with more severe head injuries Used in patients that have emerged (Ranchos IV VIII)

9 Severe TBI (GCS 3-8): Methylphenidate was associated with reductions in ICU and hospital LOS by 23% (P = 0.06 for ICU, P = for hospital stay) Moderate TBI (GCS 9-12): 26% reduction only in ICU length of stay (P = 0.05)

10 Zolpidem GABA potentiator Usually used for insomnia though generally sedating, GABA potentiators may have a paradoxical effect on severe TBI Effective in improving arousal for some severely injured patients (Sara et al, 2009; Whyte and Myers, 2009) 4.8% response rate suggested among those with disorders of consciousness (Whyte et al, 2014)

11 Address Other Factors Affecting Cognition after TBI Infection Metabolic derangements Neuroendocrine dysfunction Hypoxia Sleep/wake disturbance Sleep hygiene, melatonin, trazodone Overmedication/sedation Seizures

12 Seizure prophylaxis Given for 7 days after TBI per Evidence Based Guidelines for TBI (Marion 2006) Phenytoin and carbamazepine Associated with treatment-related impairments in cognitive and motor function (Dikmen et al. 1991; Smith et al. 1994) Levetiracetam better tolerated in TBI in the short and long term when compared with phenytoin (Jones et al. 2008; Szaflarski et al. 2010) Valproate relatively benign with respect to effects on cognition and other neurobehavioral functions among persons with TBI (Dikmen et al. 2000) Side effects: hepatic and hematological risks, alopecia, weight gain, polycystic ovarian syndrome Important to discontinue seizure prophylaxis at the end of the first week post-tbi, maintain clinical vigilance for the development of post-traumatic seizures thereafter

13 Potentially Harmful Typical antipsychotics (haloperidol) exacerbate cognitive impairments and may prolong posttraumatic amnesia (Stanislav 1997; Rao et al. 1985) Benzodiazepines impair memory and other aspects of cognition (Buffett- Jerrott and Stewart 2002) Opioids can cause memory impairments in people w/o TBI, and hence can exacerbate cognitive impairments in those with TBI

14 General Principles start low, go slow Adequate therapeutic trial Employ therapeutic trials of medications Continuous reassessment Establish a schedule for the systematic reassessment of the clinical condition for which treatment is prescribed Monitor for drug-drug interactions Augmentation Consider augmentation of partial responses to medications Symptom intensification Discontinue or lower the dose of the most recently prescribed medication if there is a worsening of the treated symptoms soon after the medication has been initiated or increased Consider consult other specialists (PM&R, Psychiatry, Neurology)

15 References Beauchamp K, Mutlak, H, Smith W, Shohami E, Stahel P. (2008) Pharmacology of Traumatic Brain Injury: Where Is the Golden Bullet?. Mol Med 14 (11-12) Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, et al. (2012) Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med 366: Giacino JT, Katz DI, Whyte J (2013). Neurorehabilitation in disorders of consciousness. Semin Neurol 33: Marion DW. Evidenced-based guidelines for traumatic brain injuries. Prog Neurol Surg. 2006;19: Moein H, Khalili HA, Keramatian K. (2006) Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. Clin. Neurol. Neurosurg.108: Rao N, Jellinek HM, Woolston DC. (1985). Agitation and closed head injury: haloperidol effects on rehabilitation outcome. Archives of Physical Medicine and Rehabilitation, 66, Sara M, Pistoia F, Mura E et al. (2009). Intrathecal baclofen in patients with persistent vegetative state: 2 hypotheses. Arch Phys Med Rehabil 90: Silver, J., Yudofsky, S. and McAllister, T. (2011). Textbook of traumatic brain injury. Washington, DC: American Psychiatric Pub. Stanislav, SW. (1997). Cognitive effects of anti-psychotic agents in persons with traumatic brain injury. Brain Injury, 11, Whyte J, Rajan R, Rosenbaum A et al. (2014). Zolpidem and restoration of consciousness. Am J Phys Med Rehabil 93: Willmott C, Ponsford J (2009). Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised crossover double blind placebo controlled inpatient trial. J Neurol Neurosurg Psychiatry 80:

16 The End

Traumatic brain injury: Pharmacotherapy options for cognitive deficits

Traumatic brain injury: Pharmacotherapy options for cognitive deficits Traumatic brain injury: Pharmacotherapy options for cognitive deficits Different medication classes improve different areas of cognitive function Mr. A, age 45, presents to the psychiatry clinic complaining

More information

Does Treatment With Amantadine Increase the Rate of Improvement of Cognitive Function in Patients Suffering From Traumatic Brain Injury?

Does Treatment With Amantadine Increase the Rate of Improvement of Cognitive Function in Patients Suffering From Traumatic Brain Injury? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Does Treatment With Amantadine Increase

More information

Pediatric Psychopharmacology

Pediatric Psychopharmacology Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders

More information

Moderator: Michele Y. Splinter, Pharm.D., BCPS Clinical Associate Professor, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma

Moderator: Michele Y. Splinter, Pharm.D., BCPS Clinical Associate Professor, University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma Central Nervous System PRN Focus Session Management of the Patient with Traumatic Brain Injury Activity No. 0217-0000-11-102-L01-P (Knowledge-Based Activity) Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention

More information

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD

Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences

More information

Managing Medical Complications of Brain Injury. Katie Turpin, NP-C

Managing Medical Complications of Brain Injury. Katie Turpin, NP-C Managing Medical Complications of Brain Injury Katie Turpin, NP-C Objectives: 1. Describe the role of the medical team in a setting focused on therapy/rehabilitation. 2. Identify common disabilities or

More information

Any interventions, where RCTs in PD are not available, are not included in the tables.

Any interventions, where RCTs in PD are not available, are not included in the tables. Tables Interventions where new studies have been published are indicated in bold italics. Changes in conclusions are indicated in italics and are highlighted in yellow. Any interventions, where RCTs in

More information

Neurocognitive Disorders Research to Emerging Therapies

Neurocognitive Disorders Research to Emerging Therapies Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia

More information

Medicating the Melon: Adjunctive Therapy after Traumatic Brain Injury

Medicating the Melon: Adjunctive Therapy after Traumatic Brain Injury Medicating the Melon: Adjunctive Therapy after Traumatic Brain Injury Kirstin Kooda, Pharm.D., BCPS, BCCCP Critical Care Pharmacist Pharmacy Grand Rounds January 24 th, 2017 Disclosures No financial relationships

More information

Appendix N: Research recommendations

Appendix N: Research recommendations Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist

More information

Critical Care Pharmacological Management of Delirium

Critical Care Pharmacological Management of Delirium Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care

More information

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist

PRESCRIBING PRACTICE IN DELIRIUM. John Warburton Critical Care Pharmacist PRESCRIBING PRACTICE IN DELIRIUM John Warburton Critical Care Pharmacist Learning outcomes Modifiable medication risk factors for delirium An appreciation of contributing factors modifiable with medicines

More information

Psychopharmacologic Approaches to Attention, Alertness, and Initiation after Brain Injury

Psychopharmacologic Approaches to Attention, Alertness, and Initiation after Brain Injury Psychopharmacologic Approaches to Attention, Alertness, and Initiation after Brain Injury Mel B. Glenn, M.D. Spaulding Rehabilitation Hospital Harvard Medical School, Boston, MA NeuroRestorative Massachusetts,

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

Neurological Subcommittee of PTAC. Meeting held 11 November (minutes for web publishing)

Neurological Subcommittee of PTAC. Meeting held 11 November (minutes for web publishing) Neurological Subcommittee of PTAC Meeting held 11 November 2015 (minutes for web publishing) Neurological Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?

USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University

More information

Activation and Recovery after Acute Brain Injury. Alan Velander, MD Neurocritical Care Ochsner Neuroscience Institute

Activation and Recovery after Acute Brain Injury. Alan Velander, MD Neurocritical Care Ochsner Neuroscience Institute Activation and Recovery after Acute Brain Injury Alan Velander, MD Neurocritical Care Ochsner Neuroscience Institute Disclosures None Disclaimers I am a neurointensivist, not an inpatient physiatrist or

More information

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points

More information

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);

More information

COGNITIVE & BEHAVIORAL DISORDERS AFTER BRAIN INJURY: PHARMACOLOGIC TREATMENT OPTIONS

COGNITIVE & BEHAVIORAL DISORDERS AFTER BRAIN INJURY: PHARMACOLOGIC TREATMENT OPTIONS COGNITIVE & BEHAVIORAL DISORDERS AFTER BRAIN INJURY: PHARMACOLOGIC TREATMENT OPTIONS MEL B. GLENN, M.D. SPAULDING REHABILITATION HOSPITAL HARVARD MEDICAL SCHOOL BOSTON, MA 1 Disclosure Advisor to TBI Model

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Neuropharmacology In TBI: What We Know & What We Don t

Neuropharmacology In TBI: What We Know & What We Don t Neuropharmacology In TBI: What We Know & What We Don t 1 Neuropharmacology in TBI: What We Know and What We Don t. Jaime M. Levine, D.O. JFK Johnson Rehab Institute Heidi Fusco, M.D. Rusk Rehabilitation

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

Outpatient management of chronic severe TBI in children

Outpatient management of chronic severe TBI in children Outpatient management of chronic severe TBI in children Nathan K. Evanson, MD PhD Assistant Professor of Pediatrics Division of Pediatric Rehabilitation Medicine Disclosures Research funding from NIH No

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

Manual of Clinical Psychopharmacology

Manual of Clinical Psychopharmacology Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

Insomnia Treatment in Brief

Insomnia Treatment in Brief Insomnia Treatment in Brief Project ECHO May 7, 2015 Jonathan Emens, M.D. Associate Professor, Departments of Psychiatry and Internal Medicine Oregon Health & Science University Staff Physician and Sleep

More information

DISORDERS OF CONSCIOUSNESS: A MULTIDISCIPLINARY TREATMENT APPROACH

DISORDERS OF CONSCIOUSNESS: A MULTIDISCIPLINARY TREATMENT APPROACH DISORDERS OF CONSCIOUSNESS: A MULTIDISCIPLINARY TREATMENT APPROACH Kathleen Crosskill, M.S., CCC-SLP, CBIS SLP Practice Leader, Brain Injury & Pediatrics, Spaulding Rehabilitation Hospital-Boston DISCLOSURE

More information

Cognitive Rehabilitation with Current Research and Transition of Care

Cognitive Rehabilitation with Current Research and Transition of Care Cognitive Rehabilitation with Current Research and Transition of Care Mike Dichiaro, MD Pediatric Rehabilitation Medicine Carin Rowan, MPT Pediatric Physical Therapy Financial Disclosures No relevant financial

More information

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic

More information

Shands Jacksonville Department of Pharmacy

Shands Jacksonville Department of Pharmacy Shands Jacksonville Department of Pharmacy Medication Use Evaluation: IV Levetiracetam Evaluation Time Period: 05/27/2013 06/24/2013 Important Aspect of Care: Care of Patients, Medication Use, Prescribing

More information

Psychiatric Treatment of the Concussed Athlete

Psychiatric Treatment of the Concussed Athlete Psychiatric Treatment of the Concussed Athlete Eastern Athletic Trainers Association January 11 th, 2015 Alexander S. Strauss, MD Centra, P.C. E-MAIL: DRSTRAUSS@ALEXSTRAUSSMD.COM Evidence Mounts Linking

More information

The Road to Rehabilitation

The Road to Rehabilitation The Road to Rehabilitation Part 6 Mapping the Way: Drug Therapy & Brain Injury Writ ten by Gregory O Shanick, MD Brain Injury Association of America Brain Injury Association of America Creating a better

More information

Augmentation and Combination Strategies in Antidepressants treatment of Depression

Augmentation and Combination Strategies in Antidepressants treatment of Depression Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported

More information

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia

Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the

More information

BIOLOGICAL TREATMENT IN PSYCHIATRY. PTE ÁOK Dept.of Psychiatry Pécs

BIOLOGICAL TREATMENT IN PSYCHIATRY. PTE ÁOK Dept.of Psychiatry Pécs BIOLOGICAL TREATMENT IN PSYCHIATRY PTE ÁOK Dept.of Psychiatry Pécs 1 SGA effects pharmacokinetic effect chemical strucrure Receptor block D2 5-HT2 α1 H-1 M Selectíve DA (D2D3) antagonists Benzamids Amisulpiride

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Critical Care Pharmacological Management of Delirium

Critical Care Pharmacological Management of Delirium Critical Care Pharmacological Management of Delirium Policy Title: in the Critical Care Unit Executive Summary: This policy provides guidance Pharmacological Management of delirium in the Critical Care

More information

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder

Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives

More information

Management of Pain related to Spinal Cord Lesion

Management of Pain related to Spinal Cord Lesion Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Agitation after TBI: Current Concepts of Pathophysiology, Assessment and Treatment

Agitation after TBI: Current Concepts of Pathophysiology, Assessment and Treatment Agitation after TBI: Current Concepts of Pathophysiology, Assessment and Treatment Brian D. Greenwald, MD Medical Director Center for Brain Injuries Associate Medical Director JFK Johnson Rehabilitation

More information

9/16/2018. Recognizing & Managing Seizures in Pediatric TBI. Objectives. Definitions and Epidemiology

9/16/2018. Recognizing & Managing Seizures in Pediatric TBI. Objectives. Definitions and Epidemiology Recognizing & Managing Seizures in Pediatric TBI UW Medicine EMS & Trauma 2018 Conference September 17 and 18, 2018 Mark Wainwright MD PhD Herman and Faye Sarkowsky Professor of Neurology Division Head,

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form

Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Pediatric Behavioral Health Medication Initiative Prior Authorization (PA) Request Form Please fax form to 617.673.0988 or mail to Tufts Health Plan, 705 Mount Auburn Street, Watertown, MA 02472, Attn:

More information

Harvard Medical School. Vice President Medical Affairs The Spaulding Rehabilitation Hospital Network Chief Physical Medicine and Rehabilitation

Harvard Medical School. Vice President Medical Affairs The Spaulding Rehabilitation Hospital Network Chief Physical Medicine and Rehabilitation Interventions to Enhance Motor Neurorecovery: Lessons Learned and Opportunities AAPMR 2015 Boston, MA Ross Zafonte,DO. Earle P. and Ida S. Charlton Chair and Professor Department of Physical Medicine and

More information

Drugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD

Drugs, Sleep & Wakefulness. Brian Koo Reena Mehra MD MS Kingman Strohl MD Drugs, Sleep & Wakefulness Brian Koo Reena Mehra MD MS Kingman Strohl MD Things To Keep In Mind Many drugs effect sleep either causing insomnia or sedation Disruption of sleep and wakefulness may not be

More information

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM. Autism Spectrum Disorder Cynthia King, MD Associate Professor of Psychiatry UNMSOM Autism Spectrum Disorder 1 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive

More information

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM

3/19/2018. Cynthia King, MD Associate Professor of Psychiatry UNMSOM Cynthia King, MD Associate Professor of Psychiatry UNMSOM 1 2 Autism Spectrum Disorder 3 Identify three behavioral health concerns in ASD Identify three common families of medication that may be supportive

More information

Quiz 35. This quiz is being published on behalf of the Education Committee of the SNACC. Start. Postoperative delirium - Px and Rx

Quiz 35. This quiz is being published on behalf of the Education Committee of the SNACC. Start. Postoperative delirium - Px and Rx Quiz 35 Postoperative delirium - Px and Rx SUNEETA GOLLAPUDY, M.D ASSOCIATE PROFESSOR, DIRECTOR OF NEUROANESTHESIA, MEDICAL COLLEGE OF WISCONSIN, MILWAUKEE, WI QUIZ TEAM: SHOBANA RAJAN, M.D; SUNEETA GOLLAPUDY,

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

Medical and Rehabilitation Innovations Neuroendocrine Screening and Hormone Replacement Therapy in Trauma Related Acquired Brain Injury

Medical and Rehabilitation Innovations Neuroendocrine Screening and Hormone Replacement Therapy in Trauma Related Acquired Brain Injury Medical and Rehabilitation Innovations Neuroendocrine Screening and Hormone Replacement Therapy in Trauma Related Acquired Brain Injury BACKGROUND Trauma related acquired brain injury (ABI) is known to

More information

The Maudsley Prescribing Guidelines in

The Maudsley Prescribing Guidelines in The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief

More information

Management of Delirium in the ICU. Yahya Shehabi

Management of Delirium in the ICU. Yahya Shehabi Management of Delirium in the ICU Yahya Shehabi Hello! Doctor, your patient is CAM + ve Good morning Dr, Am one of the RC, Just examined Mr XXX he is CAM +ve Positive what? Sir replied RC: I meant he is

More information

PROLONGED CONCUSSIONS

PROLONGED CONCUSSIONS PROLONGED CONCUSSIONS The Problem that Won t Go Away. Suzanne Hecht, MD, FACSM, CAQ University of Minnesota Team Physician: UM Athletics DISCLOSURES DJ Global: Primary Care Sports Medicine Advisory Board

More information

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018

Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Ruby Williams, M.D. Drugs, Alcohol and Sleep February 24, 2018 Objectives Describe pharmacology of commonly prescribed drugs for stimulants and hypnotics Brief review of common drugs that affect sleep

More information

Neuro Basics SLO Practice (online) Page 1 of 5

Neuro Basics SLO Practice (online) Page 1 of 5 Neuro Basics SLO Practice (online) Page 1 of 5 1) Biogenic amines include ACh, NE, EPI and? a) Melatonin b) Dopamine c) Serotonin d) Histamine e) All of the neurotransmitters listed are biogenic amines.

More information

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called

More information

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center

Best Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing

More information

The Value of Rest. Makdissi- Zurich A brief period of rest is important in the acute period following concussion.

The Value of Rest. Makdissi- Zurich A brief period of rest is important in the acute period following concussion. Treatment 2 The Value of Rest Makdissi- Zurich 2012 A brief period of rest is important in the acute period following concussion. There is no evidence however that prolonged rest is beneficial for athletes

More information

The Role of Physiatry in the Medical Management of Brain Injury. Neil Jasey, MD

The Role of Physiatry in the Medical Management of Brain Injury. Neil Jasey, MD The Role of Physiatry in the Medical Management of Brain Injury Neil Jasey, MD Disclosure I have nothing to disclose at this time. TBI Incidence & Prevalence Center for Disease Control 1.7 million Americans

More information

Pharmacological management of behavioural problems in children with acquired brain injury. A/Professor A Vance

Pharmacological management of behavioural problems in children with acquired brain injury. A/Professor A Vance Pharmacological management of behavioural problems in children with acquired brain injury Outline of presentation 1. The key types of acquired brain injury behavioural problems 2. A useful clinical model

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Guidelines and Beyond: Traumatic Brain Injury

Guidelines and Beyond: Traumatic Brain Injury Guidelines and Beyond: Traumatic Brain Injury Aimee Gowler, PharmD, BCCCP, BCPS Neuromedicine Critical Care Clinical Pharmacy Specialist UF Health Shands Disclosures I have no financial interests to disclose.

More information

Goals for sedation during mechanical ventilation

Goals for sedation during mechanical ventilation New Uses of Old Medications Gina Riggi, PharmD, BCCCP, BCPS Clinical Pharmacist Trauma ICU Jackson Memorial Hospital Disclosure I do not have anything to disclose Objectives Describe the use of ketamine

More information

Medications, By Class, in TBI

Medications, By Class, in TBI Medications, By Class, in TBI Generic/Brand Name Drawback Advantage Mood Stabilizers (anti-seizure medications) Carbamazepine (Carbatrol ) (Equetro ) (Tegretol ) Gabapentin (Neurontin ) Lamotrigine (Lamictal

More information

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS

MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,

More information

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6 in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,

More information

Part 2: Pain and Symptom Management Depression

Part 2: Pain and Symptom Management Depression Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,

More information

Treating Pain and Depression

Treating Pain and Depression Treating Pain and Depression Without Getting Depressed Joseph P, Arpaia, MD www.jparpaiamd.com More than 50% of patients with chronic pain also have clinically significant depression. Interestingly that

More information

Insomnia. Learning Objectives. Disclosure 6/7/11. Research funding: NIH, Respironics, Embla Consulting: Elsevier

Insomnia. Learning Objectives. Disclosure 6/7/11. Research funding: NIH, Respironics, Embla Consulting: Elsevier Insomnia Teofilo Lee-Chiong MD Professor of Medicine National Jewish Health University of Colorado Denver School of Medicine Learning Objectives Learn about the causes of transient and chronic Learn how

More information

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

SLEEP DISORDERS. Kenneth C. Sassower, MD Division of Sleep Medicine; Department of Neurology Massachusetts General Hospital for Children

SLEEP DISORDERS. Kenneth C. Sassower, MD Division of Sleep Medicine; Department of Neurology Massachusetts General Hospital for Children SLEEP DISORDERS Kenneth C. Sassower, MD Division of Sleep Medicine; Department of Neurology Massachusetts General Hospital for Children Distinctive Features of Pediatric Sleep Daytime sleepiness uncommon

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March

More information

Objectives. Types of Sleep Problems in Developmental Disorders

Objectives. Types of Sleep Problems in Developmental Disorders Objectives Sleep Problems in the Child with Neurodevelopmental Disorders AACPDM September 11, 2014 BRK-3 Golda Milo-Manson MD, MHSc, FRCP(C) Holland Bloorview Kids Rehabilitation Hospital Toronto, Canada

More information

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

In our patients the cause of seizures can be broadly divided into structural and systemic causes. Guidelines for the management of Seizures Amalgamation and update of previous policies 7 (Seizure guidelines, ND, 2015) and 9 (Status epilepticus, KJ, 2011) Seizures can occur in up to 15% of the Palliative

More information

Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah

Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah Faculty of dentistry Second year CND Course CNS Drugs Dr. Ali Awadallah 0912320825 Drugs that act upon the central nervous system (CNS) influence the lives of everyone, everyday. Drugs that affect the

More information

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) 475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive

More information

Patients with disorders of consciousness: how to treat them?

Patients with disorders of consciousness: how to treat them? Patients with disorders of consciousness: how to treat them? Aurore THIBAUT PhD Student Coma Science Group LUCA meeting February 25 th 2015 Pharmacological treatments Amantadine Giacino (2012) 184 TBI

More information

Medication Management in Tic Disorders. Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18

Medication Management in Tic Disorders. Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18 Medication Management in Tic Disorders Erica Greenberg, MD Pediatric Psychiatry OCD and Tic Disorders Program 7/29/18 Speaker Disclosures: No relevant disclosures (Clinical research study funded in part

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Appendix K: Evidence review flow charts

Appendix K: Evidence review flow charts K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What

More information

Greg Jicha, M.D., Ph.D. Associate Professor of Neurology The Robert T. & Nyles Y. McCowan Chair in Alzheimer s Research University of Kentucky

Greg Jicha, M.D., Ph.D. Associate Professor of Neurology The Robert T. & Nyles Y. McCowan Chair in Alzheimer s Research University of Kentucky Greg Jicha, M.D., Ph.D. Associate Professor of Neurology The Robert T. & Nyles Y. McCowan Chair in Alzheimer s Research University of Kentucky Alzheimer s Disease Center and the Sanders-Brown Center on

More information

Tofranil and Tofranil-PM (imipramine)

Tofranil and Tofranil-PM (imipramine) Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:

More information

MOST PATIENTS RECOVERING from traumatic brain

MOST PATIENTS RECOVERING from traumatic brain 42 ORIGINAL ARTICLE Effect of Severity of Post-Traumatic Confusion and Its Constituent Symptoms on Outcome After Traumatic Brain Injury Mark Sherer, PhD, Stuart A. Yablon, MD, Risa Nakase-Richardson, PhD,

More information

The future of pharmacological treatment.

The future of pharmacological treatment. The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

Dementia Pharmacotherapy

Dementia Pharmacotherapy Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on

More information

Pharmacological Treatment of Aggression in the Elderly

Pharmacological Treatment of Aggression in the Elderly Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question

More information

Mental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling

Mental Illness. Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Mental Illness Doreen L. Rasp, APN, FNP, PMHNP Advanced Behavioral Counseling Moodiness Changing Bodies Narcissism Self-Esteem Ignorant Naïve Insecure Self-Centered Independent Adolescence Disorders Affecting

More information

Delirium and Dementia. Summary

Delirium and Dementia. Summary Delirium and Dementia Paul Kettl, M.D., M.H.A. Summary DELIRIUM Acute brain failure Identify cause (meds, infection) Treat sx Poor prognostic sign DEMENTIA Chronic brain failure AD most common cause Often

More information

Delirium Monograph - Update, Spring 2014

Delirium Monograph - Update, Spring 2014 Delirium Monograph - Update, Spring 2014 Since publication of the APM monograph on Delirium in January 2012, three structured reviews have been published adding data relevant to the practice of identification,

More information

Conceptualization of Functional Outcomes Following TBI. Ryan Stork, MD

Conceptualization of Functional Outcomes Following TBI. Ryan Stork, MD Conceptualization of Functional Outcomes Following TBI Ryan Stork, MD Conceptualization of Functional Outcomes Following Traumatic Brain Injury Ryan Stork, MD Clinical Lecturer Brain Injury Medicine &

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information